iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
Globe Newswire (Wed, 8-Apr 7:00 AM ET)
Globe Newswire (Mon, 16-Mar 4:30 PM ET)
Globe Newswire (Mon, 9-Mar 7:00 AM ET)
iBio to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 24-Feb 7:00 AM ET)
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
Globe Newswire (Tue, 10-Feb 4:05 PM ET)
iBio’s Spotlight at Guggenheim Healthcare Conference Highlights Strategic Push in Obesity Innovation
Market Chameleon (Thu, 23-Oct 6:34 AM ET)
iBio Showcases Promising Activin E Antibody Data Ahead of Obesity and Cardiometabolic Conferences
Market Chameleon (Wed, 22-Oct 7:09 AM ET)
Market Chameleon (Tue, 21-Oct 6:28 AM ET)
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
Ibio trades on the NASDAQ stock market under the symbol IBIO.
As of May 1, 2026, IBIO stock price declined to $1.59 with 676,829 million shares trading.
IBIO has a beta of 2.40, meaning it tends to be more sensitive to market movements. IBIO has a correlation of 0.10 to the broad based SPY ETF.
IBIO has a market cap of $57.47 million. This is considered a Micro Cap stock.
Last quarter Ibio reported $0 in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-59,998 and missed earnings estimates by -$.02.
In the last 3 years, IBIO traded as high as $22.80 and as low as $.56.
The top ETF exchange traded funds that IBIO belongs to (by Net Assets): VTI, VXF.
IBIO has outperformed the market in the last year with a return of +50.0%, while the SPY ETF gained +31.3%. However, in the most recent history, IBIO shares have underperformed the stock market with its stock returning -24.3% in the last 3 month period and -24.6% for the last 2 week period, while SPY has returned +4.4% and +2.7%, respectively.
IBIO support price is $1.61 and resistance is $1.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBIO shares will trade within this expected range on the day.
